MedPage Today on MSNOpinion
FDA expert panels raise legal, credibility questions
Handpicked panels don't fulfill federal requirements, group argues ...
The Food and Drug Administration rejected Moderna's new flu shot. This raises questions about what it means for the future of vaccine development.
WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...
Pharmaceutical Technology on MSN
FDA’s commissioner vouchers prompt questions about award process
Despite the FDA’s CNPV scheme generating high interest, the process around how voucher awards are prioritised remains unclear ...
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Donald Trump’s administration is causing alarm across the ...
At the highest levels of the FDA, questions remain about which officials have the legal authority to sign off on drugs cleared under the Commissioner’s National Priority Voucher program, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results